AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail

AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call